JP2010510987A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010510987A5 JP2010510987A5 JP2009538419A JP2009538419A JP2010510987A5 JP 2010510987 A5 JP2010510987 A5 JP 2010510987A5 JP 2009538419 A JP2009538419 A JP 2009538419A JP 2009538419 A JP2009538419 A JP 2009538419A JP 2010510987 A5 JP2010510987 A5 JP 2010510987A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- amino
- mono
- pain
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 cyano, amino Chemical group 0.000 claims description 47
- 150000001875 compounds Chemical class 0.000 claims description 42
- 125000001424 substituent group Chemical group 0.000 claims description 40
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 39
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 30
- 125000000623 heterocyclic group Chemical group 0.000 claims description 29
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 28
- 229910052736 halogen Inorganic materials 0.000 claims description 27
- 150000002367 halogens Chemical class 0.000 claims description 27
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 24
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims description 22
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 21
- 125000004429 atom Chemical group 0.000 claims description 20
- 125000000217 alkyl group Chemical group 0.000 claims description 17
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 15
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 14
- 229910052739 hydrogen Inorganic materials 0.000 claims description 13
- 239000001257 hydrogen Substances 0.000 claims description 13
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims description 12
- 125000003118 aryl group Chemical group 0.000 claims description 10
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 10
- 229910052717 sulfur Inorganic materials 0.000 claims description 10
- 125000006568 (C4-C7) heterocycloalkyl group Chemical group 0.000 claims description 9
- 229910052760 oxygen Inorganic materials 0.000 claims description 9
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 8
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 7
- 125000001072 heteroaryl group Chemical group 0.000 claims description 7
- 229910005965 SO 2 Inorganic materials 0.000 claims description 6
- 125000002837 carbocyclic group Chemical group 0.000 claims description 5
- 125000003003 spiro group Chemical group 0.000 claims description 5
- 125000005842 heteroatom Chemical group 0.000 claims description 4
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 claims description 3
- 125000002947 alkylene group Chemical group 0.000 claims description 3
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims description 3
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 3
- 125000004076 pyridyl group Chemical group 0.000 claims description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims 34
- 208000002193 Pain Diseases 0.000 claims 33
- 230000036407 pain Effects 0.000 claims 33
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 27
- 125000004043 oxo group Chemical group O=* 0.000 claims 24
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 21
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 21
- 125000004845 (C1-C6) alkylsulfonylamino group Chemical group 0.000 claims 16
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 8
- 208000004296 neuralgia Diseases 0.000 claims 8
- 102000005962 receptors Human genes 0.000 claims 8
- 108020003175 receptors Proteins 0.000 claims 8
- 150000002431 hydrogen Chemical class 0.000 claims 7
- 208000011580 syndromic disease Diseases 0.000 claims 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 5
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims 4
- 208000008035 Back Pain Diseases 0.000 claims 4
- 208000020925 Bipolar disease Diseases 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 206010029240 Neuritis Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 230000001404 mediated effect Effects 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 208000021722 neuropathic pain Diseases 0.000 claims 4
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 3
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 3
- 125000005947 C1-C6 alkylsulfonyloxy group Chemical group 0.000 claims 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims 3
- 206010061218 Inflammation Diseases 0.000 claims 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 208000026278 immune system disease Diseases 0.000 claims 3
- 230000004054 inflammatory process Effects 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims 3
- 201000001119 neuropathy Diseases 0.000 claims 3
- 230000007823 neuropathy Effects 0.000 claims 3
- 208000033808 peripheral neuropathy Diseases 0.000 claims 3
- 125000001960 7 membered carbocyclic group Chemical group 0.000 claims 2
- 208000004998 Abdominal Pain Diseases 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 206010002383 Angina Pectoris Diseases 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 208000001387 Causalgia Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 208000002881 Colic Diseases 0.000 claims 2
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 claims 2
- 206010014020 Ear pain Diseases 0.000 claims 2
- 208000030814 Eating disease Diseases 0.000 claims 2
- 206010015958 Eye pain Diseases 0.000 claims 2
- 206010016059 Facial pain Diseases 0.000 claims 2
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 2
- 206010016654 Fibrosis Diseases 0.000 claims 2
- 206010016825 Flushing Diseases 0.000 claims 2
- 208000010412 Glaucoma Diseases 0.000 claims 2
- 201000005569 Gout Diseases 0.000 claims 2
- 206010019233 Headaches Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 206010023230 Joint stiffness Diseases 0.000 claims 2
- 206010028391 Musculoskeletal Pain Diseases 0.000 claims 2
- 208000000112 Myalgia Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 206010061310 Nerve root injury Diseases 0.000 claims 2
- 208000012902 Nervous system disease Diseases 0.000 claims 2
- 206010031009 Oral pain Diseases 0.000 claims 2
- 206010049002 Scar pain Diseases 0.000 claims 2
- 206010072005 Spinal pain Diseases 0.000 claims 2
- 206010042496 Sunburn Diseases 0.000 claims 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 150000005215 alkyl ethers Chemical class 0.000 claims 2
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- 206010003246 arthritis Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 208000028683 bipolar I disease Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 208000003295 carpal tunnel syndrome Diseases 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 208000014439 complex regional pain syndrome type 2 Diseases 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 230000007812 deficiency Effects 0.000 claims 2
- 235000014632 disordered eating Nutrition 0.000 claims 2
- 206010015037 epilepsy Diseases 0.000 claims 2
- 230000004761 fibrosis Effects 0.000 claims 2
- 231100000869 headache Toxicity 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 2
- 206010025135 lupus erythematosus Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 125000002757 morpholinyl group Chemical group 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 208000013465 muscle pain Diseases 0.000 claims 2
- 210000005036 nerve Anatomy 0.000 claims 2
- 201000009985 neuronitis Diseases 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 125000004193 piperazinyl group Chemical group 0.000 claims 2
- 125000003386 piperidinyl group Chemical group 0.000 claims 2
- 210000003994 retinal ganglion cell Anatomy 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 230000008653 root damage Effects 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 230000001953 sensory effect Effects 0.000 claims 2
- 208000019116 sleep disease Diseases 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 125000006296 sulfonyl amino group Chemical group [H]N(*)S(*)(=O)=O 0.000 claims 2
- 238000001356 surgical procedure Methods 0.000 claims 2
- 208000004371 toothache Diseases 0.000 claims 2
- 230000008733 trauma Effects 0.000 claims 2
- 230000009529 traumatic brain injury Effects 0.000 claims 2
- 239000002435 venom Substances 0.000 claims 2
- 210000001048 venom Anatomy 0.000 claims 2
- 231100000611 venom Toxicity 0.000 claims 2
- 208000009935 visceral pain Diseases 0.000 claims 2
- 125000004760 (C1-C4) alkylsulfonylamino group Chemical group 0.000 claims 1
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical group C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims 1
- 239000005977 Ethylene Chemical group 0.000 claims 1
- 125000004423 acyloxy group Chemical group 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 230000008484 agonism Effects 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 125000005278 alkyl sulfonyloxy group Chemical group 0.000 claims 1
- 125000005012 alkyl thioether group Chemical group 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 230000008485 antagonism Effects 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000000099 in vitro assay Methods 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 239000006188 syrup Substances 0.000 claims 1
- 235000020357 syrup Nutrition 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 125000006413 ring segment Chemical group 0.000 description 3
- 0 *c1n[n]cn1 Chemical compound *c1n[n]cn1 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86724806P | 2006-11-27 | 2006-11-27 | |
| PCT/US2007/024396 WO2008066789A2 (en) | 2006-11-27 | 2007-11-27 | Heteroaryl amide derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010510987A JP2010510987A (ja) | 2010-04-08 |
| JP2010510987A5 true JP2010510987A5 (enExample) | 2011-01-20 |
Family
ID=39468487
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009538419A Pending JP2010510987A (ja) | 2006-11-27 | 2007-11-27 | ヘテロアリールアミド誘導体 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US8431593B2 (enExample) |
| EP (2) | EP2591675A1 (enExample) |
| JP (1) | JP2010510987A (enExample) |
| KR (1) | KR20090094336A (enExample) |
| CN (1) | CN101621931A (enExample) |
| AU (1) | AU2007325780B9 (enExample) |
| BR (1) | BRPI0719280A2 (enExample) |
| CA (1) | CA2670636A1 (enExample) |
| CO (1) | CO6190582A2 (enExample) |
| EA (2) | EA018036B1 (enExample) |
| IL (1) | IL198827A0 (enExample) |
| MX (1) | MX2009005478A (enExample) |
| MY (1) | MY150731A (enExample) |
| NO (1) | NO20092444L (enExample) |
| NZ (1) | NZ577814A (enExample) |
| UA (1) | UA99448C2 (enExample) |
| WO (1) | WO2008066789A2 (enExample) |
| ZA (1) | ZA200904477B (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2009000117A (es) * | 2006-07-06 | 2009-01-23 | Glaxo Group Ltd | N-fenilmetil-5-oxo-prolin-2-amidas sustituidas como antagonistas de receptores p2x7 y sus metodos de uso. |
| WO2008124153A1 (en) * | 2007-04-10 | 2008-10-16 | H. Lundbeck A/S | Heteroaryl amide analogues as p2x7 antagonists |
| WO2009140101A2 (en) * | 2008-05-12 | 2009-11-19 | Boehringer Ingelheim International Gmbh | Imidazopyridine compounds useful as mmp-13 inhibitors |
| US8343977B2 (en) | 2009-12-30 | 2013-01-01 | Arqule, Inc. | Substituted triazolo-pyrimidine compounds |
| CN102464631B (zh) * | 2010-11-08 | 2016-08-10 | 中国科学院上海药物研究所 | 哌嗪取代的1,3-二取代脲类化合物及哌嗪取代的酰胺类化合物及其制备方法和用途 |
| CN103687860B (zh) | 2011-07-22 | 2016-06-08 | 埃科特莱茵药品有限公司 | 作为p2x7受体拮抗剂的杂环酰胺衍生物 |
| US9409917B2 (en) | 2012-01-20 | 2016-08-09 | Actelion Pharmaceuticals Ltd. | Heterocyclic amide derivatives as P2X7 receptor antagonists |
| WO2014091415A1 (en) * | 2012-12-12 | 2014-06-19 | Actelion Pharmaceuticals Ltd | Indole carboxamide derivatives as p2x7 receptor antagonists |
| KR102232744B1 (ko) | 2012-12-18 | 2021-03-26 | 이도르시아 파마슈티컬스 리미티드 | Ｐ２ｘ７ 수용체 길항제로서의 인돌 카르복사미드 유도체 |
| ES2616883T3 (es) | 2013-01-22 | 2017-06-14 | Actelion Pharmaceuticals Ltd. | Derivados amida heterocíclicos como antagonistas del receptor P2X7 |
| CA2896790C (en) | 2013-01-22 | 2022-05-10 | Actelion Pharmaceuticals Ltd | Heterocyclic amide derivatives as p2x7 receptor antagonists |
| ES2753386T3 (es) | 2013-03-13 | 2020-04-08 | Forma Therapeutics Inc | Derivados de 2-hidroxi-1-{4-[(4-fenil)fenil]carbonil}piperazin-1-il}etano-1-ona y compuestos relacionados como inhibidores de sintasa de ácido graso (FASN) para el tratamiento del cáncer |
| US10774051B2 (en) | 2015-04-24 | 2020-09-15 | Shionogi & Co., Ltd. | 6-membered heterocyclic derivatives and pharmaceutical composition comprising the same |
| US9802942B2 (en) | 2015-07-01 | 2017-10-31 | Northwestern University | Substituted 4-methyl-pyrrolo[1,2-A]pyrimidine-8-carboxamide compounds and uses thereof for modulating glucocerebrosidase activity |
| US10723705B2 (en) * | 2015-08-14 | 2020-07-28 | Incyte Corporation | Heterocyclic compounds and uses thereof |
| JOP20190060A1 (ar) * | 2016-09-26 | 2019-03-26 | Chugai Pharmaceutical Co Ltd | مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1 |
| WO2018074390A1 (ja) * | 2016-10-17 | 2018-04-26 | 塩野義製薬株式会社 | 二環性含窒素複素環誘導体およびそれらを含有する医薬組成物 |
| RU2764243C2 (ru) | 2017-09-22 | 2022-01-14 | ДЖУБИЛАНТ ЭПИПЭД ЭлЭлСи | Гетероциклические соединения в качестве ингибиторов PAD |
| AU2018352142B2 (en) | 2017-10-18 | 2022-08-25 | Jubilant Epipad LLC | Imidazo-pyridine compounds as PAD inhibitors |
| US11629135B2 (en) | 2017-11-06 | 2023-04-18 | Jubilant Prodell Llc | Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation |
| PT3704120T (pt) | 2017-11-24 | 2024-07-03 | Jubilant Episcribe Llc | Compostos heterocíclicos como inibidores de prmt5 |
| JP7461104B2 (ja) * | 2017-11-29 | 2024-04-03 | 中外製薬株式会社 | Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物 |
| MX2020009517A (es) | 2018-03-13 | 2021-01-20 | Jubilant Prodel LLC | Compuestos biciclicos como inhibidores de la interaccion/activacio n de pdl/pd-l1. |
| US12269822B2 (en) | 2018-07-09 | 2025-04-08 | Boehringer Ingelheim Animal Health USA Inc. | Anthelminthic heterocyclic compounds |
| FI3851436T3 (fi) * | 2018-09-10 | 2024-09-03 | Kaken Pharma Co Ltd | Uusi heteroaromaattinen amidijohdannainen ja sitä sisältävä lääke |
| TWI767148B (zh) | 2018-10-10 | 2022-06-11 | 美商弗瑪治療公司 | 抑制脂肪酸合成酶(fasn) |
| US10793554B2 (en) | 2018-10-29 | 2020-10-06 | Forma Therapeutics, Inc. | Solid forms of 4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone |
| MX2021011302A (es) | 2019-03-19 | 2022-01-19 | Boehringer Ingelheim Animal Health Usa Inc | Compuestos de aza-benzotiofeno y aza-benzofurano como antihelminticos. |
| KR20230028268A (ko) | 2020-05-29 | 2023-02-28 | 뵈링거 잉겔하임 애니멀 헬스 유에스에이 인코포레이티드 | 구충성 헤테로시클릭 화합물 |
| US11999742B2 (en) | 2021-11-01 | 2024-06-04 | Boehringer Ingelheim Vetmedica Gmbh | Substituted pyrrolo[1,2-b]pyridazines as anthelmintics |
| CN119241538A (zh) * | 2024-09-30 | 2025-01-03 | 陕西科技大学 | 一类三唑并吡啶结构的化合物、合成方法及其应用 |
Family Cites Families (103)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3701780A (en) | 1970-09-18 | 1972-10-31 | Merck & Co Inc | Imidazo(1,2-a)pyridines |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| GB1478759A (en) | 1974-11-18 | 1977-07-06 | Alza Corp | Process for forming outlet passageways in pills using a laser |
| US4034758A (en) | 1975-09-08 | 1977-07-12 | Alza Corporation | Osmotic therapeutic system for administering medicament |
| US4077407A (en) | 1975-11-24 | 1978-03-07 | Alza Corporation | Osmotic devices having composite walls |
| DK150008C (da) | 1981-11-20 | 1987-05-25 | Benzon As Alfred | Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat |
| DK151608C (da) | 1982-08-13 | 1988-06-20 | Benzon As Alfred | Fremgangsmaade til fremstilling af et farmaceutisk peroralt polydepotpraeparat med kontrolleret afgivelse |
| US4783337A (en) | 1983-05-11 | 1988-11-08 | Alza Corporation | Osmotic system comprising plurality of members for dispensing drug |
| US4587117A (en) | 1983-06-06 | 1986-05-06 | Alza Corporation | Medical device for delivering drug to pH environments greater than 3.5 |
| US4684516A (en) | 1983-08-01 | 1987-08-04 | Alra Laboratories, Inc. | Sustained release tablets and method of making same |
| US4777049A (en) | 1983-12-01 | 1988-10-11 | Alza Corporation | Constant release system with pulsed release |
| US4610870A (en) | 1984-10-05 | 1986-09-09 | E. R. Squibb & Sons, Inc. | Controlled release formulation |
| EP0186019B1 (de) | 1984-12-22 | 1993-10-06 | Schwarz Pharma Ag | Wirkstoffpflaster |
| NZ221411A (en) | 1986-08-11 | 1989-10-27 | Innovata Biomed Ltd | Pharmaceutical compositions containing microcapsules and a surfactant |
| US4994276A (en) | 1988-09-19 | 1991-02-19 | Edward Mendell Co., Inc. | Directly compressible sustained release excipient |
| IL87710A (en) | 1987-09-18 | 1992-06-21 | Ciba Geigy Ag | Covered floating retard form for controlled release in gastric juice |
| AU3432689A (en) | 1988-03-24 | 1989-10-16 | Bukh Meditec A/S | Controlled release composition |
| US5296236A (en) | 1988-09-16 | 1994-03-22 | Recordati S.A., Chemical And Pharmaceutical Company | Controlled release therapeutic system for a liquid pharmaceutical formulations |
| US5128143A (en) | 1988-09-19 | 1992-07-07 | Edward Mendell Co., Inc. | Sustained release excipient and tablet formulation |
| US5202128A (en) | 1989-01-06 | 1993-04-13 | F. H. Faulding & Co. Limited | Sustained release pharmaceutical composition |
| US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
| US5071607A (en) | 1990-01-31 | 1991-12-10 | Alza Corporatino | Method and apparatus for forming a hole in a drug dispensing device |
| FR2663224B1 (fr) | 1990-06-14 | 1995-01-20 | Applicationes Farmaceuticas Sa | Forme galenique parenterale. |
| US5681585A (en) | 1991-12-24 | 1997-10-28 | Euro-Celtique, S.A. | Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5376384A (en) | 1992-12-23 | 1994-12-27 | Kinaform Technology, Inc. | Delayed, sustained-release pharmaceutical preparation |
| US5662933A (en) | 1993-09-09 | 1997-09-02 | Edward Mendell Co., Inc. | Controlled release formulation (albuterol) |
| GB9407386D0 (en) | 1994-04-14 | 1994-06-08 | Smithkline Beecham Plc | Pharmaceutical formulation |
| US6447796B1 (en) | 1994-05-16 | 2002-09-10 | The United States Of America As Represented By The Secretary Of The Army | Sustained release hydrophobic bioactive PLGA microspheres |
| WO1995035298A1 (en) | 1994-06-21 | 1995-12-28 | Otsuka Pharmaceutical Factory, Inc. | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVE |
| US5612053A (en) | 1995-04-07 | 1997-03-18 | Edward Mendell Co., Inc. | Controlled release insufflation carrier for medicaments |
| GB9519363D0 (en) | 1995-09-22 | 1995-11-22 | Euro Celtique Sa | Pharmaceutical formulation |
| JP3735741B2 (ja) * | 1995-11-24 | 2006-01-18 | 株式会社大塚製薬工場 | 縮環ピリミジン誘導体 |
| AU2068797A (en) | 1996-01-29 | 1997-08-20 | Edward Mendell Co. Inc. | Sustained release excipient |
| US5773031A (en) | 1996-02-27 | 1998-06-30 | L. Perrigo Company | Acetaminophen sustained-release formulation |
| DE69717453T2 (de) * | 1996-06-06 | 2003-07-10 | Otsuka Pharmaceutical Factory, Inc. | Amid derivate |
| US5891474A (en) | 1997-01-29 | 1999-04-06 | Poli Industria Chimica, S.P.A. | Time-specific controlled release dosage formulations and method of preparing same |
| US6133434A (en) | 1997-04-28 | 2000-10-17 | Glaxo Group Limited | Purinergic receptor |
| SE9704544D0 (sv) | 1997-12-05 | 1997-12-05 | Astra Pharma Prod | Novel compounds |
| SE9704545D0 (sv) | 1997-12-05 | 1997-12-05 | Astra Pharma Prod | Novel compounds |
| JP4000433B2 (ja) * | 1998-01-29 | 2007-10-31 | 株式会社大塚製薬工場 | ピラゾロ〔１，５−ａ〕ピリミジン誘導体 |
| US6156342A (en) | 1998-05-26 | 2000-12-05 | Andex Pharmaceuticals, Inc. | Controlled release oral dosage form |
| US6197347B1 (en) | 1998-06-29 | 2001-03-06 | Andrx Pharmaceuticals, Inc. | Oral dosage for the controlled release of analgesic |
| SE9803871D0 (sv) | 1998-11-11 | 1998-11-11 | Pharmacia & Upjohn Ab | Therapeutic method and formulation |
| WO2000044754A1 (en) * | 1999-01-29 | 2000-08-03 | Sumitomo Chemical Company, Limited | Fat accumulation inhibitory agents |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| EP1210328A1 (en) * | 1999-08-31 | 2002-06-05 | Neurogen Corporation | Fused pyrrolecarboxamides: a new class of gaba brain receptor ligands |
| EP1207860B1 (en) | 1999-09-02 | 2007-10-24 | Nostrum Pharmaceuticals, Inc. | Controlled release pellet formulation |
| JP2003508420A (ja) | 1999-09-02 | 2003-03-04 | ノストラム・ファーマスーティカルズ・インコーポレイテッド | 経口投与に適した、制御された放出の経口用量 |
| US6355653B1 (en) | 1999-09-06 | 2002-03-12 | Hoffmann-La Roche Inc. | Amino-triazolopyridine derivatives |
| GB9921933D0 (en) | 1999-09-17 | 1999-11-17 | Univ Gent | Solid shaped articles comprising biologically active substances and a method for their production |
| FR2801308B1 (fr) | 1999-11-19 | 2003-05-09 | Oreal | COMPOSITIONS DE TEINTURE DE FIBRES KERATINIQUES CONTENANT DE DES 3-AMINO PYRAZOLO-[1,(-a]-PYRIDINES, PROCEDE DE TEINTURE, NOUVELLES 3-AMINO PYRAZOLO-[1,5-a]-PYRIDINES |
| SE9904505D0 (sv) | 1999-12-09 | 1999-12-09 | Astra Pharma Prod | Novel compounds |
| CN1173975C (zh) | 2000-04-27 | 2004-11-03 | 山之内制药株式会社 | 咪唑并吡啶衍生物 |
| GB0013737D0 (en) | 2000-06-07 | 2000-07-26 | Astrazeneca Ab | Novel compounds |
| US6491950B1 (en) | 2000-08-07 | 2002-12-10 | Kos Pharmaceuticals, Inc. | Controlled release pharmaceutical composition |
| TWI312347B (en) | 2001-02-08 | 2009-07-21 | Eisai R&D Man Co Ltd | Bicyclic nitrogen-containing condensed ring compounds |
| SE0100568D0 (sv) | 2001-02-20 | 2001-02-20 | Astrazeneca Ab | Compounds |
| US6524615B2 (en) | 2001-02-21 | 2003-02-25 | Kos Pharmaceuticals, Incorporated | Controlled release pharmaceutical composition |
| HUP0401292A3 (en) | 2001-04-27 | 2011-01-28 | Eisai R & D Man Co | Pyrazolo[1,5-a]pyridines, pharmaceutical compositions containing the same and process for preparation thereof |
| WO2003035649A1 (en) | 2001-10-22 | 2003-05-01 | Pfizer Japan Inc. | Imidazopyridine compounds as 5-ht4 receptor modulators |
| SE0103836D0 (sv) | 2001-11-16 | 2001-11-16 | Astrazeneca Ab | Novel compounds |
| CA2476681A1 (en) * | 2002-02-19 | 2003-08-28 | Bruce N. Rogers | Fused bicyclic-n-bridged-heteroaromatic carboxamides for the treatment of disease |
| EP1485384A1 (en) | 2002-03-13 | 2004-12-15 | Pharmacia & Upjohn Company LLC | Pyrazolo(1,5-a)pyridine derivatives as neurotransmitter modulators |
| SE0200920D0 (sv) | 2002-03-25 | 2002-03-25 | Astrazeneca Ab | Novel compounds |
| JP2004002826A (ja) | 2002-04-24 | 2004-01-08 | Sankyo Co Ltd | 高分子イミダゾピリジン誘導体 |
| US7037902B2 (en) * | 2002-07-03 | 2006-05-02 | Receptron, Inc. | Affinity small molecules for the EPO receptor |
| MY139563A (en) | 2002-09-04 | 2009-10-30 | Bristol Myers Squibb Co | Heterocyclic aromatic compounds useful as growth hormone secretagogues |
| AR041292A1 (es) * | 2002-09-19 | 2005-05-11 | Schering Corp | Pirazolopiridinas como inhibidores de quinasa dependientes de ciclina |
| JP2006504728A (ja) | 2002-10-03 | 2006-02-09 | スミスクライン ビーチャム コーポレーション | ピラソロピリジン誘導体系治療用化合物 |
| GB0312609D0 (en) | 2003-06-02 | 2003-07-09 | Astrazeneca Ab | Novel compounds |
| FR2856061A1 (fr) | 2003-06-11 | 2004-12-17 | Chrysalon | Derives polycycliques ortho-condenses de l'aminopyrrole a substituant electroattracteur chimiotheques combinatoires desdits derives et leur procede d'obtention |
| ATE458485T1 (de) * | 2003-07-11 | 2010-03-15 | Proteologics Inc | Ubiquitin-ligase-hemmer und verwandte verfahren |
| TW200510373A (en) | 2003-07-14 | 2005-03-16 | Neurogen Corp | Substituted quinolin-4-ylamine analogues |
| SE0302192D0 (sv) | 2003-08-08 | 2003-08-08 | Astrazeneca Ab | Novel compounds |
| US7538120B2 (en) | 2003-09-03 | 2009-05-26 | Array Biopharma Inc. | Method of treating inflammatory diseases |
| US7144907B2 (en) | 2003-09-03 | 2006-12-05 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
| JP2007509180A (ja) * | 2003-10-21 | 2007-04-12 | インスパイアー ファーマシューティカルズ，インコーポレイティド | 疼痛を治療するための、非ヌクレオチド組成物および方法 |
| ES2328047T3 (es) | 2004-03-19 | 2009-11-06 | Warner-Lambert Company Llc | Derivados de imidazopiridina e imidazopirimidina como agentes antibacterianos. |
| CA2565211A1 (en) * | 2004-04-29 | 2005-11-24 | Abbott Laboratories | Amino-tetrazoles analogues and methods of use |
| JPWO2005108399A1 (ja) | 2004-05-10 | 2008-03-21 | 萬有製薬株式会社 | イミダゾピリジン化合物 |
| SA05260265A (ar) * | 2004-08-30 | 2005-12-03 | استرازينيكا ايه بي | مركبات جديدة |
| EP1799680A2 (en) | 2004-10-07 | 2007-06-27 | Warner-Lambert Company LLC | Triazolopyridine derivatives as antibacterial agents |
| WO2006094235A1 (en) | 2005-03-03 | 2006-09-08 | Sirtris Pharmaceuticals, Inc. | Fused heterocyclic compounds and their use as sirtuin modulators |
| MY147647A (en) | 2005-03-21 | 2012-12-31 | S Bio Pte Ltd | Imidazo [1,2-a] pyridine derivatives : preparation and pharmaceutical applications |
| US7402596B2 (en) | 2005-03-24 | 2008-07-22 | Renovis, Inc. | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof |
| WO2006110516A1 (en) | 2005-04-11 | 2006-10-19 | Abbott Laboratories | Acylhydrazide p2x7 antagonists and uses thereof |
| US20070155738A1 (en) * | 2005-05-20 | 2007-07-05 | Alantos Pharmaceuticals, Inc. | Heterobicyclic metalloprotease inhibitors |
| US7572807B2 (en) | 2005-06-09 | 2009-08-11 | Bristol-Myers Squibb Company | Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors |
| MX2008002014A (es) | 2005-08-15 | 2008-03-27 | Hoffmann La Roche | Derivados de piperidina y piperazina como antagonistas de p2x3. |
| JP2009507795A (ja) | 2005-08-31 | 2009-02-26 | スミスクライン ビーチャム コーポレーション | 化合物 |
| US7578855B2 (en) | 2005-11-09 | 2009-08-25 | L'ORéAL S.A. | Composition for dyeing keratin fibers comprising at least one cationic 3-amino-pyrazolopyridine derivative, and methods of use thereof |
| JP4913157B2 (ja) | 2006-01-17 | 2012-04-11 | エフ．ホフマン−ラ ロシュ アーゲー | ＧＡＢＡレセプター経由でのアルツハイマー病の処置に有用なアリール−イソオキサゾール−４−イル−イミダゾ［１，２−ａ］ピリジン誘導体 |
| PE20070946A1 (es) | 2006-01-25 | 2007-10-16 | Smithkline Beecham Corp | COMPUESTOS DERIVADOS DE IMIDAZO[1,2-a]PIRIDINA COMO MODULADORES DEL RECEPTOR DE QUIMIOQUINA (CXCR4) |
| JP2009524689A (ja) | 2006-01-25 | 2009-07-02 | スミスクライン ビーチャム コーポレーション | 化合物 |
| MX2008012617A (es) | 2006-03-31 | 2008-10-10 | Novartis Ag | Compuestos organicos. |
| WO2008019309A1 (en) | 2006-08-04 | 2008-02-14 | Metabasis Therapeutics, Inc. | Novel inhibitors of fructose 1,6-bisphosphatase |
| WO2008115259A2 (en) | 2006-08-10 | 2008-09-25 | Rigel Pharmaceuticals, Inc. | Derivatives of benzoxadiazole suitable for the treatment of cell proliferative diseases |
| WO2008027812A2 (en) | 2006-08-28 | 2008-03-06 | Forest Laboratories Holdings Limited | Imidazopyridine and imidazopyrimidine derivatives |
| CA2661850A1 (en) | 2006-09-01 | 2008-03-06 | Kyorin Pharmaceutical Co., Ltd. | Pyrazolopyridine carboxamide derivative and phosphodiesterase (pde) inhibitor containing the same |
| WO2008029152A2 (en) | 2006-09-08 | 2008-03-13 | Summit Corporation Plc | Treatment of duchenne muscular dystrophy |
| CA2666658C (en) | 2006-10-06 | 2015-01-20 | Boehringer Ingelheim International Gmbh | Chymase inhibitors |
| CA2670083A1 (en) * | 2006-11-20 | 2008-05-29 | Alantos Pharmaceuticals Holding, Inc. | Heterobicyclic metalloprotease inhibitors |
-
2007
- 2007-11-27 EP EP13150025.8A patent/EP2591675A1/en not_active Withdrawn
- 2007-11-27 MY MYPI20092150 patent/MY150731A/en unknown
- 2007-11-27 EA EA200970516A patent/EA018036B1/ru not_active IP Right Cessation
- 2007-11-27 AU AU2007325780A patent/AU2007325780B9/en not_active Ceased
- 2007-11-27 EA EA201300152A patent/EA201300152A1/ru unknown
- 2007-11-27 KR KR1020097013490A patent/KR20090094336A/ko not_active Ceased
- 2007-11-27 UA UAA200906538A patent/UA99448C2/ru unknown
- 2007-11-27 ZA ZA200904477A patent/ZA200904477B/xx unknown
- 2007-11-27 BR BRPI0719280-0A patent/BRPI0719280A2/pt not_active IP Right Cessation
- 2007-11-27 MX MX2009005478A patent/MX2009005478A/es active IP Right Grant
- 2007-11-27 NZ NZ577814A patent/NZ577814A/en not_active IP Right Cessation
- 2007-11-27 WO PCT/US2007/024396 patent/WO2008066789A2/en not_active Ceased
- 2007-11-27 JP JP2009538419A patent/JP2010510987A/ja active Pending
- 2007-11-27 CA CA002670636A patent/CA2670636A1/en not_active Abandoned
- 2007-11-27 CN CN200780049692A patent/CN101621931A/zh active Pending
- 2007-11-27 US US12/516,480 patent/US8431593B2/en not_active Expired - Fee Related
- 2007-11-27 EP EP07862234.7A patent/EP2096923B1/en active Active
-
2009
- 2009-05-19 IL IL198827A patent/IL198827A0/en unknown
- 2009-06-26 CO CO09066902A patent/CO6190582A2/es active IP Right Grant
- 2009-06-26 NO NO20092444A patent/NO20092444L/no not_active Application Discontinuation
-
2013
- 2013-01-29 US US13/812,960 patent/US20130172549A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010510987A5 (enExample) | ||
| AU2020266592B2 (en) | Substituted cyclolakyls as modulators of the integrated stress pathway | |
| ES2622138T3 (es) | Nuevos derivados de pirimidina condensados para la inhibición de la actividad tirosina quinasa | |
| TW202019900A (zh) | Ptpn11抑制劑 | |
| CA3180819A1 (en) | Substituted aminothiazoles as dgkzeta inhibitors for immune activation | |
| JP2010535816A5 (enExample) | ||
| JP2010533736A5 (enExample) | ||
| US20090209536A1 (en) | Aminoquinazoline cannabinoid receptor modulators for treatment of disease | |
| ES2636652T3 (es) | Compuestos de tetrahidrocarbazol y carbazol carboxamida sustituidos útiles como inhibidores de quinasa | |
| IL274406B2 (en) | Modulators of the integrated stress pathway | |
| IL274367B2 (en) | Combined pressure pathway modulators | |
| EA034931B1 (ru) | Индолкарбоксамидные соединения | |
| BR112020008836A2 (pt) | Moduladores da via de estresse integrada | |
| JP2015535251A (ja) | 電位作動型ナトリウムチャネルにおいて選択的活性を有するベンゾオキサゾリノン化合物 | |
| EA024109B1 (ru) | Ингибиторы протеинкиназ | |
| WO2020009971A1 (en) | Pikfyve inhibitors | |
| CA3008485C (en) | Alkynyl dihydroquinoline sulfonamide compounds | |
| JP5822079B2 (ja) | 疼痛治療剤 | |
| CA3174865A1 (en) | Quinazoline compound and preparation method, application, and pharmaceutical composition thereof | |
| CA3091202A1 (en) | Chromene derivatives as inhibitors of tcr-nck interaction | |
| JP2025519119A (ja) | Ｍｅｋ阻害剤及びその使用 | |
| JP2019504016A (ja) | アルキルジヒドロキノリンスルホンアミド化合物 | |
| US20210000830A1 (en) | CANCER TREATMENT METHOD USING Trk INHIBITOR AND KINASE INHIBITOR IN COMBINATION | |
| CN117580835A (zh) | Mek抑制剂及其用途 | |
| US20220153735A1 (en) | Orai Channel Inhibitors |